Rapid Medical

Neurovascular Devices

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in August 2008 by Shimon Eckhouse and Ronen Eckhouse, Rapid Medical operates with 51–200 employees. The company has raised $82.31M across 7 funding rounds from 14 investors.

Business overview

Rapid Medical develops neurovascular medical devices designed to enhance patient care and meet physician needs. Its product portfolio includes distal access catheters, adjustable remodeling mesh for microcatheters, and steerable guidewires. The company's offerings, such as the Tigertriever 13, Comaneci, and Drivewire (Columbus outside the U.S.), are utilized in the health tech and life sciences sector to treat vascular diseases with less invasive interventional approaches, serving markets in Europe, the United States, India, and China.

Strategic signal

In May 2026, Rapid Medical underwent a significant internal restructuring to adapt to a fundamental shift in its business model, with the company now operating as an AI-driven entity. This strategic pivot indicates a move towards integrating artificial intelligence into its operations, potentially transforming its approach to neurovascular device development and market strategy, signaling a forward-looking adaptation to technological advancements.

Company Intelligence Q&A

What was a significant recent strategic development for Rapid Medical?
In May 2026, Rapid Medical announced an internal restructuring to align with a fundamental change in its business model, transitioning to operate as an AI-driven company.
What was a key market expansion for Rapid Medical in late 2023?
In December 2023, Rapid Medical announced Japanese approval and an exclusive partnership with Kaneka for its TIGERTRIEVER device, expanding its presence in the Asian market.
What regulatory milestone did Rapid Medical achieve in July 2022?
In July 2022, Rapid Medical gained FDA clearance for its adjustable thrombectomy device, marking a significant regulatory approval for its neurovascular technology.
What was a notable clinical trial enrollment for Rapid Medical in June 2022?
In June 2022, Rapid Medical enrolled the first patient in the DISTALS Stroke Trial, aiming to expand treatment options for new ischemic stroke patient populations.

External links